Image Place holder

Jad Chahoud, MD, MPH

Specialty: Medical Oncology
Program: Genitourinary Oncology

Overview

Cancer Focus: Kidney (Renal Cell) Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer

Dr. Chahoud completed his Internal Medicine Residency at the University of Texas Health Science Center and completed his hematology and medical oncology fellowship at the University of Texas MD Anderson Cancer Center in Houston. Dr. Chahoud's clinical expertise includes advanced stage genitourinary malignancies, with a specific focus on advanced kidney and penile cancer. Dr. Chahoud's research aims to understand the role of viral infections and the immune microenvironment in genitourinary cancers. He received funding from the Conquer Cancer Foundation through the ASCO Young Investigator Award in 2018 to study viral and immune biomarkers for metastasis and poor survival in penile squamous cell carcinoma. His research interest is focused on providing precision care through biomarker research to determine the most effective treatment strategy, and the investigation of novel therapies for patients with advanced renal, prostate, testicular and penile cancer.  He's fluent in English, Spanish, French and Arabic.


Education & Training

Board Certification:

  • Internal Medicine
  • Medical Oncology

Fellowship:

  • University of Texas MD Anderson Cancer Center -

Residency:

  • University of Texas Health Science Center -

Medical School:

  • Lebanese University Faculty of Medical Sciences - MD
Awards
Start Year: 2015 End Year: Hematology Opportunities for the Next Generation of Research Scientists (HONORS), Sponsor: American Society of Hematology
Start Year: 2017 End Year: 2018 Conquer Cancer Foundation Merit Award, Sponsor: American Society of Oncology
Start Year: 2013 End Year: Best Abstract Award, Sponsor: International Congress of Chemotherapy and Infection
Start Year: 2018 End Year: 2019 Conquer Cancer Foundation Merit Award, Sponsor: The American Society of Oncology
Start Year: 2018 End Year: 2018 Society for Transnational Oncology, Sponsor: Rising Star in Oncology
Start Year: 2018 End Year: 2019 Conquer Cancer Foundation Young Investigator Award, Sponsor: American Society of Oncology
Participating Trials

CLINICAL TRIAL 20377
A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors
Condition: Genitourinary
Intervention: ADT (); BMS-936558 (Nivolumab); Firmagon (); Lupron (leuprolide acetate); Nivolumab (Opdivo); Taxotere (docetaxel); Zoladex (); docetaxel (); goserelin acetate (Zoladex)
Open

CLINICAL TRIAL 20614
A Phase III, Multicneter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib versus Cabozantinib Alone in Patients with Inoperable, Locally, Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment
Condition: Genitourinary
Intervention: Atezolizumab (Tecentriq); Cabozantinib (XL 184)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs. 2021 Oct.39(5):1405-1410. Pubmedid: 33770291.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 Oct.206(4):924-932. Pubmedid: 34032503.
  • Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Chahoud J, Briganti A, Salvioni R, Montorsi F, Necchi A, Spiess PE. Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. J Urol. 2021 Oct.206(4):960-969. Pubmedid: 34032492.
  • Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Chahoud J, Briganti A, Salvioni R, Montorsi F, Necchi A, Spiess PE. Reply by Authors. J Urol. 2021 Oct.206(4):969. Pubmedid: 34379451.
  • Safa H, Tamil M, Spiess PE, Manley B, Pow-Sang J, Gilbert S, Safa F, Gonzalez BD, Oswald LB, Semaan A, Diab A, Chahoud J. Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. J Natl Cancer Inst. 2021 May.113(5):532-542. Pubmedid: 33146385. Pmcid: PMC8096374.
  • Chahoud J, Gleber-Netto FO, McCormick BZ, Rao P, Lu X, Guo M, Morgan MB, Chu RA, Martinez-Ferrer M, Eterovic AK, Pickering CR, Pettaway CA. Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2021 May.27(9):2560-2570. Pubmedid: 33441293.
  • Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2021 May. Pubmedid: 33994165.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2021 May.4(5):e2111329. Pubmedid: 34032854. Pmcid: PMC8150693.
  • Chahoud J, Kohli M, Spiess PE. Management of Advanced Penile Cancer. Mayo Clin Proc. 2021 Mar.96(3):720-732. Pubmedid: 33308870.
  • Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol. 2021 Jul.39(7):2409-2415. Pubmedid: 32936333. Pmcid: PMC8101019.
  • Chakiryan NH, Kimmel GJ, Kim Y, Johnson JO, Clark N, Hajiran A, Chang A, Aydin AM, Zemp L, Katende E, Chahoud J, Ferrall-Fairbanks MC, Spiess PE, Francis N, Fournier M, Dhillon J, Park JY, Wang L, Mulé JJ, Altrock PM, Manley BJ. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021 Jul.13(15). Pubmedid: 34359645. Pmcid: PMC8345222.
  • Hajiran A, Zemp L, Aydin AM, Cheryian SK, Pow-Sang JM, Chahoud J, Spiess PE. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urol Oncol. 2021 Jan.39(1):72.e1-72.e5. Pubmedid: 33036902.
  • Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 Feb.39(2):134.e9-134.e16. Pubmedid: 33187886.
  • Adashek JJ, Zhang Y, Skelton WP, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?. Front Oncol. 2021 Feb.10:627025. Pubmedid: 33643921. Pmcid: PMC7902859.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Li R, Sexton W, Manley BJ, Gilbert SM. Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder. Urol Oncol. 2021 Aug. Pubmedid: 34426068.
  • Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 Apr.204(1):96-106. Pubmedid: 33346915. Pmcid: PMC7944355.
  • Chakiryan NH, Kimmel GJ, Kim Y, Hajiran A, Aydin AM, Zemp L, Katende E, Nguyen J, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, El-Kenawi A, Mulé J, Altrock PM, Manley BJ. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PLoS One. 2021 Apr.16(4):e0245415. Pubmedid: 33882057. Pmcid: PMC8059840.
  • Chahoud J, Tamil M, Necchi A. Second line salvage systemic therapy for advanced penile cancer. Urol Oncol. 2020 Sep. Pubmedid: 32950396.
  • Aydin AM, Chahoud J, Adashek JJ, Azizi M, Magliocco A, Ross JS, Necchi A, Spiess PE. Understanding genomics and the immune environment of penile cancer to improve therapy. Nat Rev Urol. 2020 Oct.17(10):555-570. Pubmedid: 32812000.
  • Ahmed ME, Falasiri S, Hajiran A, Chahoud J, Spiess PE. The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy. J Clin Med. 2020 Oct.9(10). Pubmedid: 33080912. Pmcid: PMC7603091.
  • Berglund A, Amankwah EK, Kim YC, Spiess PE, Sexton WJ, Manley B, Park HY, Wang L, Chahoud J, Chakrabarti R, Yeo CD, Luu HN, Pietro GD, Parker A, Park JY. Influence of gene expression on survival of clear cell renal cell carcinoma. Cancer Med. 2020 Nov.9(22):8662-8675. Pubmedid: 32986937. Pmcid: PMC7666730.
  • Huang T, Cheng X, Chahoud J, Sarhan A, Tamboli P, Rao P, Guo M, Manyam G, Zhang L, Xiang Y, Han L, Shang X, Deng P, Luo Y, Lu X, Feng S, Ferrer MM, Alan Wang Y, DePinho RA, Pettaway CA, Lu X. Effective combinatorial immunotherapy for penile squamous cell carcinoma. Nat Commun. 2020 May.11(1):2124. Pubmedid: 32358507. Pmcid: PMC7195486.
  • Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist. 2020 Mar.25(3):252-258. Pubmedid: 32162795. Pmcid: PMC7066696.
  • Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?. J Urol. 2020 Jun.203(6):1147-1155. Pubmedid: 31928407.
  • Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Reply by Authors. J Urol. 2020 Jun.203(6):1155. Pubmedid: 32176595.
  • Terrisse S, Karamouza E, Parker CC, Sartor AO, James ND, Pirrie S, Collette L, Tombal BF, Chahoud J, Smeland S, Erikstein B, Pignon JP, Fizazi K, Le Teuff G. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. JAMA Oncol. 2020 Feb.6(2):206-216. Pubmedid: 31830233. Pmcid: PMC6990736.
  • Chahoud J, Skelton WP, Spiess PE, Walko C, Dhillon J, Gage KL, Johnstone PAS, Jain RK. Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab. Front Oncol. 2020 Dec.10:615298. Pubmedid: 33425770. Pmcid: PMC7793656.
  • Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist. 2019 Sep. Pubmedid: 31501271.
  • Chahoud J, Pickering CR, Pettaway CA. Genetics and penile cancer: recent developments and implications. Curr Opin Urol. 2019 Jul.29(4):364-370. Pubmedid: 31045928.
  • Chahoud J, Zhang M, Pisters LL, Lin SC, Lin SH, Tu SM. Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clin Genitourin Cancer. 2018 Oct.16(5):325-327. Pubmedid: 29807831.
  • Chahoud J, Zhang M, Shah A, Lin SH, Pisters LL, Tu SM. Managing seminomatous and nonseminomatous germ cell tumors. Curr Opin Oncol. 2018 May.30(3):181-188. Pubmedid: 29538040.
  • Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated Results of Rituximab Pre- and Post-BEAM with or without Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2018 May.24(10):2304-2311. Pubmedid: 29476021. Pmcid: PMC5955837.
  • Chahoud J, Rieber AG, Tyring SK. The β-HPV Subtypes-Cornerstone of the Next-Generation Vaccine. JAMA Oncol. 2017 May.3(5):594-595. Pubmedid: 27893031.
  • Chahoud J, Sharif Yakan A, Saad H, Kanj SS. Right-Sided Infective Endocarditis and Pulmonary Infiltrates: An Update. Cardiol Rev. 2016 Sep.24(5):230-237. Pubmedid: 26501991.
  • Chahoud J, Semaan A, Chen Y, Cao M, Rieber AG, Rady P, Tyring SK. Association Between β-Genus Human Papillomavirus and Cutaneous Squamous Cell Carcinoma in Immunocompetent Individuals-A Meta-analysis. JAMA Dermatol. 2016 Dec.152(12):1354-1364. Pubmedid: 26720285.
  • Chahoud J, Semaan A, Rieber A. Wealth, Health Expenditure, and Cancer: A National Perspective. J Natl Compr Canc Ne. 2016 Aug.14(8):972-978. Pubmedid: 27496113.
  • Chahoud J, Semaan A, Rieber A. Counterpoint: Wealth, Health Expenditure, and Cancer-Translating Research Into Efficient Policies. J Natl Compr Canc Ne. 2016 Aug.14(8):1043. Pubmedid: 27496120.
  • Chahoud J, Semaan A, Almoosa KF. Ventilator-associated events prevention, learning lessons from the past: A systematic review. Heart Lung. 2015 May.44(3):251-259. Pubmedid: 25686517.
  • Chahoud J, Mrad J, Semaan A, Asmar R. PREVALENCE OF DIABETES MELLITUS AMONG PATIENTS WITH ESSENTIAL ARTERIAL HYPERTENSION. J Med Liban. 2015 Apr.63(2):74-80. Pubmedid: 26164975.
  • Chahoud J, Kanafani Z, Kanj SS. Surgical site infections following spine surgery: eliminating the controversies in the diagnosis. Front Med (Lausanne). 2014 Mar.1:7. Pubmedid: 25705620. Pmcid: PMC4335387.
  • Chahoud J, Kanafani ZA, Kanj SS. Management of candidaemia and invasive candidiasis in critically ill patients. Int J Antimicrob Agents. 2013 Jun.42 Suppl:S29-S35. Pubmedid: 23664579.
  • Zekan DS, Dahman A, Hajiran AJ, Luchey AM, Chahoud J, Spiess PE. Prognostic predictors of lymph node metastasis in penile cancer: a systematic review. Int Braz J Urol. 47(5):943-956. Pubmedid: 33650835. Pmcid: PMC8321459.

Grants

Title: The Feasibility of an Educational and Monitoring Smart-Phone Application for Patients with Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy
Sponsor: Pfizer, Inc.
PI: Chahoud, J.

Patient Comments
Overall Satisfaction
4.7

68 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments